GTx (NASDAQ:GTXI) Receives Media Sentiment Rating of 0.26

News coverage about GTx (NASDAQ:GTXI) has trended positive on Saturday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GTx earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.2305321730471 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of GTx (NASDAQ GTXI) traded up 2.1673% during trading on Friday, hitting $7.9997. 18,107 shares of the stock traded hands. GTx has a 1-year low of $0.65 and a 1-year high of $9.71. The firm has a 50-day moving average of $8.17 and a 200-day moving average of $5.81. The firm’s market capitalization is $128.46 million.

GTx (NASDAQ:GTXI) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter. On average, equities analysts forecast that GTx will post ($1.16) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “GTx (NASDAQ:GTXI) Receives Media Sentiment Rating of 0.26” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/gtx-gtxi-receives-daily-news-sentiment-rating-of-0-26.html.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply